Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome profiling in early-stage luminal breast cancer

ABSTRACT: Transcriptome profiling in early-stage luminal breast cancer

PROVIDER: PRJNA935263 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23462611.fastq.gz	Fastqsanger.gz
	SRR23462612.fastq.gz	Fastqsanger.gz
	SRR23462613.fastq.gz	Fastqsanger.gz
	SRR23462614.fastq.gz	Fastqsanger.gz
	SRR23462615.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 67

Similar Datasets

miRNA transcriptome profiling in early-stage luminal breast cancer

Project description:miRNA transcriptome profiling in early-stage luminal breast cancer

| PRJNA935266 | ENA

miRNA transcriptome profiling in early-stage luminal breast cancer

Project description:Oxysterols, oxidized derivatives of cholesterol, act in breast cancer (BC) as selective estrogen receptor modulators and affect cholesterol homeostasis, drug transport, nuclear and cell receptors, and other signaling proteins. Using overlapping data from patients with early-stage estrogen receptor-positive BC—high-coverage targeted DNA sequencing (99 patients, 113 genes), mRNA sequencing (67 patients), and full miRNome by microarrays (123 patients)—we describe complex mRNA-miRNA and miRNA-miRNA interaction (correlation) networks, with validation in two carefully curated public datasets (n=538 in total) and 11 databases. The ESR1-CH25H-INSIG1-ABCA9 axis was the most prominent, being interconnected through hsa-miR-125b-5p, but also hsa-miR-99a-5p, hsa-miR-100-5p, hsa miR 143 3p, hsa-199b-5p, hsa-miR-376a-3p, and hsa-miR-376c-3p. Mutations in SC5D, CYP46A1, and its functionally linked gene set were associated with multiple differentially expressed genes. STARD5 was upregulated in patients with positive lymph node status. High expression of miR-19b-3p was weakly associated with poor survival in multiple datasets. This is the first detailed dedicated study of interactions between DNA variation and mRNA expression of oxysterol-related genes, the miRNA transcriptome, and clinical factors in BC.

2023-08-02 | GSE225292 | GEO

Pan-cancer drivers are recurrent transcriptional regulatory heterogeneities in early-stage luminal breast cancer

Project description:Pan-cancer drivers are recurrent transcriptional regulatory heterogeneities in early-stage luminal breast cancer

| PRJNA614000 | ENA

Early-stage breast cancer

Project description:Copy number alteration profiling of human early-stage (stage I and II) breast cancers. We aimed to describe the commonly occurred chromosome alterations in early-stage breast cancer (stage I and II) and to explore the implications of the recurrently altered regions (RAR) on the patient prognosis. For this purpose, we analyzed the DNA copy number alterations (CNAs) across the whole genome using oligoarray-comparative genomic hybridization (CGH) in the discovery set of EBC patients.

2012-05-09 | GSE37839 | GEO

miRNA expression profiling in early stage breast cancer

Project description:MiRNA profiling from whole blood (EDTA) was used to identify a miRNA profile applicable for early stage breast cancer detection

2012-02-02 | GSE31309 | GEO

Early-stage breast cancer

2012-05-08 | E-GEOD-37839 | biostudies-arrayexpress

Degradome/Peptidome Early-stage Breast Cancer

Project description:Pooled blood plasma hi-res MS/MS top-down dataset from early-stage breast cancer patients; LC 1 Part 3

2010-10-19 | PRD000185 | Pride

Pan-cancer drivers are recurrent transcriptional regulatory heterogeneities in early-stage luminal breast cancer

Project description:The heterogeneous composition of solid tumors is known to impact disease progression and response to therapy. Malignant cells coexist in different regulatory states that can be accessed transcriptomically by RNA sequencing, but single-cell methods have many caveats related to sensitivity, noise, and sample handling. We revised a statistical fluctuation analysis called stochastic profiling to combine with 10-cell RNA sequencing, which was designed for laser-capture microdissection (LCM) and extended here for immuno-LCM. When applied to a cohort of late-onset, early-stage luminal breast cancers, the integrated approach identified thousands of candidate regulatory heterogeneities. Intersecting the candidates from different tumors yielded a relatively stable set of 710 recurrent heterogeneously expressed genes (RHEGs) that were significantly variable in >50% of patients. RHEGs were not confounded by dissociation artifacts, cell cycle oscillations, or driving mutations for breast cancer. Rather, we detected RHEG enrichments for epithelial-to-mesenchymal transition genes and, unexpectedly, the latest pan-cancer assembly of driver genes across all cancer types. Heterogeneous transcriptional regulation conceivably provides a faster, reversible mechanism for malignant cells to sample the effects of potential oncogenes or tumor suppressors on cancer hallmarks.

2021-01-19 | GSE147356 | GEO

miRNA expression profiling in early stage breast cancer

Project description:MiRNA profiling from whole blood (EDTA) was used to identify a miRNA profile applicable for early stage breast cancer detection In the study presented here, a consecutively collected, well-defined cohort of 48 patients with early stage breast cancer (invasive ductal carcinoma) at diagnosis was compared with a cohort of 57 healthy individuals for known homo sapiens miRNAs (mirbase 15).

2012-02-02 | E-GEOD-31309 | biostudies-arrayexpress

Metabolic detection of early-stage breast cancer through absolute quantitative metabolomics and machine learning

Project description:To achieve the best outcomes, breast cancer necessitates robust strategies for early detection. However, reliable blood-based tests for identifying early-stage disease remains elusive. Here we have employed plasma metabolomics and machine learning techniques to establish a non-invasive metabolic approach for early detection of breast cancer.

2023-11-06 | MSV000093325 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data